Davita Inc vs NetEase Inc — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while NetEase Inc trades at $122.32 (market cap $76.90B). The key difference: NetEase Inc is far larger — about 6.8× Davita Inc's market cap, and NetEase Inc pays a 2.43% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and NetEase Inc for 74 Days on average.
| DVA | NTES | |
|---|---|---|
Market Cap | $11.28B | $76.90B |
Volume | 650,294 | 494,839 |
Sector | Health | Technology |
52-Week High | $240.96 | $152.85 |
52-Week Low | $103.87 | $109.26 |
Typical Hold Time | 113 Days | 74 Days |
Enterprise Value | $24.00B | $52.62B |
Dividend Yield | — | 2.43% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
NTES trades at $119.60, up 0.45% today, with a neutral technical signal. The company reported Q2 2026 revenue of $4.4 billion, up 8% year-over-year, though EPS missed estimates due to investment losses. Gross margins improved significantly, and the balance sheet remains strong with $137.58 billion in cash. Revenue growth has been steady, with 2025 revenue reaching $112.63 billion and net income at $33.76 billion.
The outlook is positive given strong profitability, a robust balance sheet, and analyst consensus favoring a buy rating with a $168 price target. Risks include earnings volatility, competitive pressures in gaming, and macroeconomic headwinds affecting Chinese tech stocks. The stock presents a value opportunity with a P/E of 16.06, below industry averages.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →